Effect of remimazolam on the dynamics of laparoscopic surgery in patients with hypertension

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100051486

Enrollment

Unknown

Registered

2021-09-24

Start date

2021-10-01

Completion date

Unknown

Last updated

2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

Experimental group:Remimazolam

Control group1:Propofol

Control group2:Etomidate

Experimental group2:Remimazolam+Propofol

Experimental group3:Remimazolam+Etomidate

Eligibility

Sex/Gender

Male

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with primary or secondary hypertension; 2. ASA classification is II or III; 3. BMI 1828 kg/m2; 4. Aged 18 to 65 years; 5. The type of surgery is laparoscopic surgery.

Exclusion criteria

Exclusion criteria: 1. Critically ill patients; 2. Those suffering from allergic diseases or serious neuropsychiatric diseases; 3. Those who have resistance or allergic reactions or contraindications to benzodiazepines or other anesthetics; 4. Alcoholism and psychotropic drug addiction; 5. Emergency surgery and any unplanned surgery; 6. Liver function impairment [(AST)/(ALT) >= 2.5.

Design outcomes

Primary

Measure	Time frame
hemodynamic;	—

Countries

China

Contacts

Public ContactWang Zhongyu

The First Affiliated Hospital of Zhengzhou University

17335582496@163.com+86 13937165514

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026